Opdivo NSCLC, HCC data showcased at ASCO

Bristol-Myers Squibb Co. (NYSE:BMY) shed $4.55 to $64.60 on Friday after data presented at the American Society of Clinical Oncology (ASCO) meeting detailed the survival benefit from Opdivo nivolumab in patients with non-squamous non-small cell lung cancer (NSCLC). The first Opdivo data to treat hepatocellular carcinoma (HCC) were also presented at the meeting.

Data from the Phase III CheckMate -057 study showed that treatment with Opdivo led to median overall survival (OS) of 12.2 months vs. 9.4 months in previously-treated non-squamous NSCLC patients receiving docetaxel (HR=0.73; 96% CI: 0.59, 0.89; p=0.00155). In a subgroup of patients with PD-L1 expression in >1% of their tumor cells, the median OS in the Opdivo arm exceeded 17 months vs. 9 months for docetaxel (HR=0.59; 95% CI: 0.43, 0.81). In April, BMS had said it stopped CheckMate -057 early after reviewers concluded Opdivo met the primary endpoint of superiority to docetaxel in improving OS in previously-treated non-squamous NSCLC patients. ...